These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18790211)

  • 1. Management of highly sensitized patients: capitol medical center experience.
    Amante AJ; Ejercito R
    Transplant Proc; 2008 Sep; 40(7):2274-80. PubMed ID: 18790211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
    Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
    N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttransplant immunosuppression in highly sensitized patients.
    Akalin E
    Contrib Nephrol; 2009; 162():27-34. PubMed ID: 19001811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
    Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients.
    Jordan SC; Peng A; Vo AA
    Contrib Nephrol; 2009; 162():13-26. PubMed ID: 19001810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intravenous immune globulin and rituximab for desensitization of highly human leukocyte antigen-sensitized patients awaiting kidney transplantation.
    Rehman S; Meier-Kriesche HU; Scornik J
    Transplantation; 2010 Oct; 90(8):932; author reply 932-3. PubMed ID: 20962612
    [No Abstract]   [Full Text] [Related]  

  • 8. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab.
    Chikaraishi T; Sasaki H; Tsutsumi H; Miyano S; Nakazawa R; Nakano T; Kitajima K; Kudo H; Takahashi T; Sato Y; Kimura K
    Transplant Proc; 2008 Dec; 40(10):3445-7. PubMed ID: 19100409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients.
    Montgomery RA; Lonze BE; Jackson AM
    Curr Opin Organ Transplant; 2011 Aug; 16(4):439-43. PubMed ID: 21666478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of sensitized patients awaiting renal transplantation: does sequential therapy of intravenous immunoglobulin and simvastatin offer a solution?
    Mahmoud KM; Sobh MA; El Shenawy F; Isamil AM; El-Magd MA; Hassan NA; El-Agroudy AE; Sheashaa HA; Opelz G; Ghoneim MA
    Eur J Pharmacol; 2007 Apr; 561(1-3):202-5. PubMed ID: 17296177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of the highly sensitized patient.
    Claas FH; Doxiadis II
    Curr Opin Immunol; 2009 Oct; 21(5):569-72. PubMed ID: 19682882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
    Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
    Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presensitization: the problem and its management.
    Jordan SC; Pescovitz MD
    Clin J Am Soc Nephrol; 2006 May; 1(3):421-32. PubMed ID: 17699241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience.
    Magee CC; Felgueiras J; Tinckam K; Malek S; Mah H; Tullius S
    Transplantation; 2008 Jul; 86(1):96-103. PubMed ID: 18622284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation.
    Bingaman AW; Murphey CL; Palma-Vargas J; Wright F
    Transplantation; 2008 Dec; 86(12):1864-8. PubMed ID: 19104435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
    Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
    Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible?
    Faenza A; Fuga G; Bertelli R; Scolari MP; Buscaroli A; Stefoni S
    Transplant Proc; 2008; 40(6):1833-8. PubMed ID: 18675064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients.
    Zachary AA; Montgomery RA; Ratner LE; Samaniego-Picota M; Haas M; Kopchaliiska D; Leffell MS
    Transplantation; 2003 Nov; 76(10):1519-25. PubMed ID: 14657698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
    Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
    Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.